Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes

Benzinga_recent_news02-17

Ocular Therapeutix Inc. (NASDAQ:OCUL) shares are down during Tuesday's premarket session following a significant announcement regarding their Axpaxli treatment for wet age-related macular degeneration...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612500524?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/17/Close-up-Of-A-Womans-Eyes.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-02-17 22:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612500524","market":"us","top_or_hot":-1,"title":"Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes","media":"Benzinga_recent_news","content":"<div>\n<p>Ocular Therapeutix Inc. (NASDAQ:OCUL) shares are down during Tuesday's premarket session following a significant announcement regarding their Axpaxli treatment for wet age-related macular degeneration...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/02/50650687/ocular-therapeutix-drug-shows-promise-in-eye-disorder-but-falls-short-of-investor-hopes\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-17 22:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/02/50650687/ocular-therapeutix-drug-shows-promise-in-eye-disorder-but-falls-short-of-investor-hopes><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocular Therapeutix Inc. (NASDAQ:OCUL) shares are down during Tuesday's premarket session following a significant announcement regarding their Axpaxli treatment for wet age-related macular degeneration...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/02/50650687/ocular-therapeutix-drug-shows-promise-in-eye-disorder-but-falls-short-of-investor-hopes\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1861559042.SGD","symbol_name":"日兴方舟颠覆性创新基金B SGD","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/02/50650687/ocular-therapeutix-drug-shows-promise-in-eye-disorder-but-falls-short-of-investor-hopes","article_id":"2612500524","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/17/Close-up-Of-A-Womans-Eyes.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/02/50650687/ocular-therapeutix-drug-shows-promise-in-eye-disorder-but-falls-short-of-investor-hopes","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2612500524","pubTimestamp":1771337700,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Ocular Therapeutix shares tumble after Axpaxli wet AMD trial data disappoints investors, despite meeting key Phase 3 goals.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","OCUL":"Ocular Therapeutix","DAMD":"2倍做空AMD ETF-Defiance","LU0823421333.USD":"BNP PARIBAS DISRUPTIVE TECHNOLOGY \"C\" (USD) ACC","LU1303367103.USD":"摩根大通多经理另类基金 A (acc)","LU0823421416.USD":"BNP PARIBAS DISRUPTIVE TECHNOLOGY \"C\" (USD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU2098885051.SGD":"JPMorgan Funds - Multi-Manager Alternatives A (acc) SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2458330169.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A\" (SGD) ACC","LU1880398554.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) INC","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU0109392836.USD":"富兰克林科技股A","LU2458330243.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A-H1\" (SGDHDG) ACC","BK4529":"IDC概念","LU1861558580.USD":"日兴方舟颠覆性创新基金B","LU1951198990.SGD":"Natixis Thematics AI & Robotics Fund H-R/A SGD-H","AMUU":"2倍做多AMD ETF-Direxion","BK4566":"资本集团","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","AMYY":"GraniteShares YieldBOOST AMD ETF","LU1951200564.SGD":"Natixis Thematics AI & Robotics Fund R/A SGD","LU1923623000.USD":"Natixis Thematics AI & Robotics Fund R/A USD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","BK4605":"半导体精选","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","BK4007":"制药","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU1316542783.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0889565833.HKD":"FRANKLIN TECHNOLOGY \"A\" (HKD) ACC","LU0642271901.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD-H","BK4575":"芯片概念","IE00B5949003.HKD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A\" (HKD) ACC","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU2089985449.USD":"MANULIFE GF GLOBAL SEMICONDUCTOR OPPORTUNITIES \"AA\" (USD) ACC","LU0082616367.USD":"摩根大通美国科技A（dist）","LU2360106780.USD":"BGF WORLD TECHNOLOGY \"A4\" (USD) INC","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","LU1803068979.SGD":"FTIF - Franklin Technology A (acc) SGD-H1","BK4612":"AI芯片","LU2931357623.SGD":"MANULIFE GF GLOBAL SEMICONDUCTOR OPPORTUNITIES \"AA\" (SGDHDG) ACC","BK4614":"Manus概念股","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","BK4573":"虚拟现实","BK4532":"文艺复兴科技持仓","BK4543":"AI","BK4512":"苹果概念","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1852331112.SGD":"Blackrock World Technology Fund A2 SGD-H","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","BK4534":"瑞士信贷持仓","BK4141":"半导体产品","LU1880398471.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) ACC","BK4139":"生物科技","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","AMDD":"1倍做空AMD ETF-Direxion","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2355687059.USD":"NORDEA 1 GLOBAL IMPACT  \"BP\" (USD) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","AMDG":"2倍做多AMD ETF- Leverage Shares","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0081259029.USD":"UBS (LUX) EQUITY FUND - TECH OPPORTUNITY \"P\" (USD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","AMDU":"Defiance Leveraged Long + Income AMD ETF","BK4554":"元宇宙及AR概念","LU0056508442.USD":"贝莱德世界科技基金A2","AMDW":"Roundhill AMD WeeklyPay ETF","LU2054465674.USD":"UBS (LUX) KEY SELEC SICAV DIGITAL TRANSFORMATION T \"P\" (USD) ACC","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","AMDY":"AMD期权收益策略ETF-YieldMax","BK4585":"ETF&股票定投概念","LU2250418816.HKD":"BGF WORLD TECHNOLOGY \"A\" (HKD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0274383776.USD":"MANULIFE GF US SMALL CAP EQUITY \"AA\" (USD) INC","LU0719512351.SGD":"JPMorgan Funds - US Technology A (acc) SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4588":"碎股"},"translate_title":"眼部治疗药物在眼部疾病方面显示出前景，但未达到投资者的希望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMDD":0.6,"AMYY":0.6,"DAMD":0.6,"AMUU":0.6,"AMDU":0.6,"AMDY":0.6,"AMDG":0.6,"AMDW":0.6,"OCUL":1.97},"content_text":"Ocular Therapeutix Inc. (NASDAQ:OCUL) shares are down during Tuesday's premarket session following a significant announcement regarding their Axpaxli treatment for wet age-related macular degeneration (AMD).\nThe stock is trading lower as data did not meet investor expectations.\nSTAT News reported that Axpaxli's durability advantage over the active control was smaller than investors had anticipated, potentially raising questions about its commercial outlook in wet age-related macular degeneration, a market with established effective therapies.\nOcular Therapeutix shared topline results from the SOL-1 Phase 3 superiority trial of Axpaxli (OTX-TKI).\nAfter a loading phase, the SOL-1 trial compared a single dose of Axpaxli (0.45 mg) to a single dose of Regeneron Pharmaceuticals Inc.'s (NASDAQ:REGN) Eylea (aflibercept 2 mg).\nThe SOL-1 Phase 3 superiority trial demonstrated that 74.1% of subjects treated with Axpaxli maintained vision at Week 36, compared to 65.9% in the aflibercept arm, marking a notable risk difference of 17.5% (p=0.0006).\nIn addition to achieving the primary endpoint, Axpaxli showed either statistical significance or numerical superiority to aflibercept (2 mg) in key secondary and prespecified exploratory endpoints.\nThe trial also highlighted that 80.6% of subjects in the Axpaxli arm were rescue-free at Week 24, significantly outperforming the aflibercept group.\nAxpaxli met its Week 52 durability assessment with high statistical significance.\nThe proportion of subjects who maintained vision at Week 52 was 65.9% in the Axpaxli arm compared to 44.2% in the aflibercept (2 mg) arm, with a risk difference of 21.1% compared to aflibercept (2 mg) subjects, and with an observed difference of 21.7%.\nOcular intends to submit a New Drug Application (NDA) based on SOL-1 data, subject to planned formal discussions with the U.S. FDA.\nIf approved, Axpaxli could be the first tyrosine kinase inhibitor (TKI) to be commercialized in wet AMD, and potentially the only therapy with a superiority label and best-in-disease durability.\nThe complementary SOL-R Phase 3 non-inferiority trial of Axpaxli in wet AMD will continue as planned, with topline data expected in the first quarter of 2027.\nCurrently, Ocular Therapeutix is trading 26.46% lower in premarket trading, reflecting a significant shift from its previous close. The stock has increased by 23.33% over the past 12 months, indicating a generally positive long-term trend despite recent volatility. Its 52-week range shows a high of $16.44 and a low of $5.79, positioning the stock closer to its lows than its highs.\nThe RSI level is not available, but the MACD status is also not provided, indicating a lack of clear momentum signals at this time. Without these indicators, traders should be cautious, as the absence of momentum signals can suggest uncertainty in price direction.\nThe stock carries a Buy Rating with an average price target of $21.00. Recent analyst moves include:\nOCUL Price Action: Ocular Therapeutix shares were down 25.45% at $6.62 during premarket trading on Tuesday, according to Benzinga Pro data.\nImage via Shutterstock/ New Africa\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612500524","isCrawlerRequest":true}